• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种多状态模型用于研究乳腺癌的化疗耐药性,以描述其表型动力学特征。

A multi-state model of chemoresistance to characterize phenotypic dynamics in breast cancer.

机构信息

Department of Biomedical Engineering, The University of Texas at Austin, Austin, Texas, 78712, USA.

Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas, 78712, USA.

出版信息

Sci Rep. 2018 Aug 13;8(1):12058. doi: 10.1038/s41598-018-30467-w.

DOI:10.1038/s41598-018-30467-w
PMID:30104569
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6089904/
Abstract

The development of resistance to chemotherapy is a major cause of treatment failure in breast cancer. While mathematical models describing the dynamics of resistant cancer cell subpopulations have been proposed, experimental validation has been difficult due to the complex nature of resistance that limits the ability of a single phenotypic marker to sufficiently identify the drug resistant subpopulations. We address this problem with a coupled experimental/modeling approach to reveal the composition of drug resistant subpopulations changing in time following drug exposure. We calibrate time-resolved drug sensitivity assays to three mathematical models to interrogate the models' ability to capture drug response dynamics. The Akaike information criterion was employed to evaluate the three models, and it identified a multi-state model incorporating the role of population heterogeneity and cellular plasticity as the optimal model. To validate the model's ability to identify subpopulation composition, we mixed different proportions of wild-type MCF-7 and MCF-7/ADR resistant cells and evaluated the corresponding model output. Our blinded two-state model was able to estimate the proportions of cell types with an R-squared value of 0.857. To the best of our knowledge, this is the first work to combine experimental time-resolved drug sensitivity data with a mathematical model of resistance development.

摘要

化疗耐药的发展是乳腺癌治疗失败的主要原因。虽然已经提出了描述耐药癌细胞亚群动力学的数学模型,但由于耐药的复杂性限制了单一表型标志物充分识别耐药亚群的能力,因此实验验证一直很困难。我们采用耦合的实验/建模方法来解决这个问题,以揭示药物暴露后耐药亚群随时间变化的组成。我们对三种数学模型进行了时间分辨药物敏感性测定,以检查这些模型捕获药物反应动力学的能力。Akaike 信息准则用于评估这三个模型,结果表明,包含群体异质性和细胞可塑性作用的多状态模型是最佳模型。为了验证模型识别亚群组成的能力,我们混合了不同比例的野生型 MCF-7 和 MCF-7/ADR 耐药细胞,并评估了相应的模型输出。我们的盲法两状态模型能够以 0.857 的 R 平方值估计细胞类型的比例。据我们所知,这是首次将实验时间分辨药物敏感性数据与耐药发展的数学模型相结合的工作。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/25c8004b4206/41598_2018_30467_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/d4e4504581c7/41598_2018_30467_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/a90450b381cf/41598_2018_30467_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/0472b45bb7fa/41598_2018_30467_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/fb0dbb5fa375/41598_2018_30467_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/25c8004b4206/41598_2018_30467_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/d4e4504581c7/41598_2018_30467_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/a90450b381cf/41598_2018_30467_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/0472b45bb7fa/41598_2018_30467_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/fb0dbb5fa375/41598_2018_30467_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e9d8/6089904/25c8004b4206/41598_2018_30467_Fig5_HTML.jpg

相似文献

1
A multi-state model of chemoresistance to characterize phenotypic dynamics in breast cancer.一种多状态模型用于研究乳腺癌的化疗耐药性,以描述其表型动力学特征。
Sci Rep. 2018 Aug 13;8(1):12058. doi: 10.1038/s41598-018-30467-w.
2
miRNA expression patterns in chemoresistant breast cancer tissues.化疗耐药乳腺癌组织中的微小RNA表达模式
Biomed Pharmacother. 2014 Oct;68(8):935-42. doi: 10.1016/j.biopha.2014.09.011. Epub 2014 Oct 5.
3
Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.载多柔比星的基于表面活性剂的纳米粒克服癌症的多药耐药性。
Int J Nanomedicine. 2018 Mar 21;13:1723-1736. doi: 10.2147/IJN.S157368. eCollection 2018.
4
Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.柴胡皂苷D可诱导乳腺癌MCF-7/阿霉素细胞中P-糖蛋白介导的多药耐药性的逆转。
Pathol Res Pract. 2017 Jul;213(7):848-853. doi: 10.1016/j.prp.2017.01.022. Epub 2017 Feb 3.
5
FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.FGFR4将乳腺癌中的葡萄糖代谢与化疗耐药性联系起来。
Cell Physiol Biochem. 2018;47(1):151-160. doi: 10.1159/000489759. Epub 2018 May 10.
6
Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.可还原交联透明质酸纳米粒用于主动靶向和智能递药系统对耐药 CD44+人乳腺癌肿瘤异种移植瘤的治疗。
J Control Release. 2015 May 10;205:144-54. doi: 10.1016/j.jconrel.2015.01.012. Epub 2015 Jan 14.
7
Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.分子碘会损害化学抗性机制,增强阿霉素的保留,并诱导 MCF-7 细胞中对低剂量阿霉素有抗性的 CD44+/CD24+ 和 E-钙黏蛋白+/波形蛋白+亚群的下调。
Oncol Rep. 2017 Nov;38(5):2867-2876. doi: 10.3892/or.2017.5934. Epub 2017 Sep 1.
8
High Expression of SIRT1 Associates with the Doxorubicin Resistance of Breast Cancer through the Activation of Akt.SIRT1 的高表达通过激活 Akt 与乳腺癌的多柔比星耐药性相关。
Anticancer Agents Med Chem. 2020;20(1):94-102. doi: 10.2174/1871520619666191028100405.
9
Paris saponin VII reverses chemoresistance in breast MCF-7/ADR cells.巴黎七叶皂甙逆转 MCF-7/ADR 细胞的化疗耐药性。
J Ethnopharmacol. 2019 Mar 25;232:47-54. doi: 10.1016/j.jep.2018.12.018. Epub 2018 Dec 12.
10
Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.白藜芦醇通过增加阿霉素的细胞内流入量来增强其对多药耐药性人乳腺癌细胞的化学敏感性。
Biochim Biophys Acta. 2014 Jan;1840(1):615-25. doi: 10.1016/j.bbagen.2013.10.023. Epub 2013 Oct 24.

引用本文的文献

1
Quantitative measurement of phenotype dynamics during cancer drug resistance evolution using genetic barcoding.利用基因条形码对癌症耐药性进化过程中的表型动态进行定量测量。
Nat Commun. 2025 Jun 20;16(1):5282. doi: 10.1038/s41467-025-59479-7.
2
Computational identification of surface markers for isolating distinct subpopulations from heterogeneous cancer cell populations.计算鉴定用于从异质癌细胞群体中分离不同亚群的表面标记物。
NPJ Syst Biol Appl. 2024 Oct 17;10(1):120. doi: 10.1038/s41540-024-00441-6.
3
Computational identification of surface markers for isolating distinct subpopulations from heterogeneous cancer cell populations.

本文引用的文献

1
The automatic construction of bootstrap confidence intervals.自助法置信区间的自动构建。
J Comput Graph Stat. 2020;29(3):608-619. doi: 10.1080/10618600.2020.1714633. Epub 2020 Mar 12.
2
Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer.精准医学与不精确治疗:乳腺癌化疗的计算模型
Transl Oncol. 2018 Jun;11(3):732-742. doi: 10.1016/j.tranon.2018.03.009. Epub 2018 Apr 16.
3
Precision Oncology: Between Vaguely Right and Precisely Wrong.精准肿瘤学:似是而非与精准谬误之间。
通过计算识别表面标志物以从异质性癌细胞群体中分离出不同亚群
bioRxiv. 2024 Jun 2:2024.05.28.596337. doi: 10.1101/2024.05.28.596337.
4
Development of adaptive anoikis resistance promotes metastasis that can be overcome by CDK8/19 Mediator kinase inhibition.适应性失巢凋亡抗性的发展促进转移,而CDK8/19中介激酶抑制可克服这种转移。
bioRxiv. 2023 Dec 6:2023.12.04.569970. doi: 10.1101/2023.12.04.569970.
5
Cell Population Growth Kinetics in the Presence of Stochastic Heterogeneity of Cell Phenotype.细胞表型随机异质性存在下的细胞群体生长动力学
ArXiv. 2023 Oct 19:arXiv:2301.03782v2.
6
Cytotoxic and chemomodulatory effects of Phyllanthus niruri in MCF-7 and MCF-7 breast cancer cells.菲律宾肾蕨对 MCF-7 和 MCF-7 乳腺癌细胞的细胞毒性和化学调节作用。
Sci Rep. 2023 Feb 15;13(1):2683. doi: 10.1038/s41598-023-29566-0.
7
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III.利用 PBPK/PD 模型对黑色素瘤中 MDM2 和 MEK 抑制剂协同组合的体外/体内转化:第三部分。
Int J Mol Sci. 2023 Jan 23;24(3):2239. doi: 10.3390/ijms24032239.
8
Assessing chemotherapy dosing strategies in a spatial cell culture model.在空间细胞培养模型中评估化疗给药策略。
Front Oncol. 2022 Nov 24;12:980770. doi: 10.3389/fonc.2022.980770. eCollection 2022.
9
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I.利用 PBPK/PD 模型对黑色素瘤中 MDM2 和 MEK 抑制剂协同组合的体外/体内转化:第一部分。
Int J Mol Sci. 2022 Oct 26;23(21):12984. doi: 10.3390/ijms232112984.
10
In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part II.在黑色素瘤中使用 PBPK/PD 模型对 MDM2 和 MEK 抑制剂协同组合进行的体外/体内转化:第二部分。
Int J Mol Sci. 2022 Oct 8;23(19):11939. doi: 10.3390/ijms231911939.
Cancer Res. 2017 Dec 1;77(23):6473-6479. doi: 10.1158/0008-5472.CAN-17-0448. Epub 2017 Nov 21.
4
A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer.三阴性乳腺癌多柔比星治疗的预测性数学建模方法研究。
Sci Rep. 2017 Jul 18;7(1):5725. doi: 10.1038/s41598-017-05902-z.
5
Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!细胞表型调控和重编程的数学模型:让癌细胞再次变得敏感!
Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):167-175. doi: 10.1016/j.bbcan.2017.04.001. Epub 2017 Apr 7.
6
Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.通过适应性策略而非分子特性定义癌症亚群为肿瘤内进化提供了新见解。
Cancer Res. 2017 May 1;77(9):2242-2254. doi: 10.1158/0008-5472.CAN-16-2844. Epub 2017 Mar 1.
7
Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.依赖糖酵解使 BRAF 突变型黑色素瘤对靶向 BRAF 抑制的反应增强。
Sci Rep. 2017 Feb 16;7:42604. doi: 10.1038/srep42604.
8
How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient.当患者面临化疗药物耐药威胁时如何使用该化疗药物。
PLoS Biol. 2017 Feb 9;15(2):e2001110. doi: 10.1371/journal.pbio.2001110. eCollection 2017 Feb.
9
Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success.临床肿瘤学中的多尺度建模:成功的机遇与障碍
Ann Biomed Eng. 2016 Sep;44(9):2626-41. doi: 10.1007/s10439-016-1691-6. Epub 2016 Jul 6.
10
Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.癌症中的细胞群体异质性与耐药性演变:生物学与数学评估、理论治疗优化
Biochim Biophys Acta. 2016 Nov;1860(11 Pt B):2627-45. doi: 10.1016/j.bbagen.2016.06.009. Epub 2016 Jun 20.